GSK/Valeant's Potiga gets unanimous support from US FDA advisory panel
This article was originally published in Scrip
Executive Summary
The US FDA's peripheral and central nervous system drugs advisory committee on 11 August smoothed the way for approval of the anti-epileptic Potiga (ezogabine, previously known as retigabine), which is being developed under an agreement between GlaxoSmithKline and Valeant (which is in the process of being acquired by the Canada's largest drug maker, Biovail).